Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Junji Murai"'
Autor:
Akihiro Yoshimura, Takayuki Takeda, Nobutaka Kataoka, Keiko Tanimura, Mototaka Fukui, Yusuke Chihara, Shota Takei, Hayato Kawachi, Kentaro Nakanishi, Yuta Yamanaka, Nobuyo Tamiya, Ryoichi Honda, Naoko Okura, Takahiro Yamada, Kiyoaki Uryu, Junji Murai, Shinsuke Shiotsu, Hiroshige Yoshioka, Tadaaki Yamada, Takayasu Kurata, Koichi Takayama
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionThe efficacy of second-line immune checkpoint inhibitor (ICI) therapy is limited in non-small cell lung cancer (NSCLC) patients with ≤ 49% PD-L1 expression. Although chemoimmunotherapy is a promising strategy, platinum-based chemotherap
Externí odkaz:
https://doaj.org/article/8d57729f3fdc4dbb893f9ca297d30e84
Publikováno v:
Cureus.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b286e350fd70cb82b1f11449f75242ca
https://doi.org/10.7759/cureus.39499
https://doi.org/10.7759/cureus.39499
Autor:
Yusuke Tachibana, Tadaaki Yamada, Taisuke Tsuji, Junji Murai, Kazuki Jinno, Shoki Matsumoto, Aosa Sasada, Shiho Goda, Ayaka Omura, Shinsuke Shiotsu, Tatsuya Yuba, Chieko Takumi, Noriya Hiraoka, Koichi Takayama
Recent studies have reported that coronavirus disease-2019 (COVID-19) vaccination can exacerbate asthma. Status asthmaticus sometimes induces takotsubo cardiomyopathy. We present a case of takotsubo cardiomyopathy triggered by asthma exacerbation aft
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4604ed7e1b3dc105699ace3d7b92cc75
https://doi.org/10.22541/au.167454760.04808166/v1
https://doi.org/10.22541/au.167454760.04808166/v1
Autor:
Tae Hata, Chikara Sakaguchi, Keita Hirano, Hiroshi Kobe, Masaki Ishida, Takayuki Nakano, Yusuke Tachibana, Junji Murai, Masamitsu Enomoto, Tomoki Tanaka, Nobuyo Tamiya, Shinsuke Shiotsu, Takayuki Takeda, Tadaaki Yamada, Toshihide Yokoyama, Michiko Tsuchiya, Yukio Nagasaka
BackgroundPatients with epidermal growth factor receptor (EGFR)-mutated, advanced non-small cell lung cancer have received immunochemotherapy as one of the treatment options after tyrosine kinase inhibitor (TKI) failure. We examined the efficacy of i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29d224d0ed08ccc6f6299bc89a881225
https://doi.org/10.21203/rs.3.rs-1590589/v1
https://doi.org/10.21203/rs.3.rs-1590589/v1